Data science company Cogitativo Inc on Wednesday announced the "Surge Centers: The Top 10 L.A. County Neighborhoods at Greatest Risk as COVID Infections Rise " report that identifies the top ten neighborhoods in Los Angeles County at greatest risk of COVID infections including the highly contagious Delta variant.
The company added that the top five L.A. County cities at greatest risk of increased hospitalizations are Palmdale, Inglewood, Malibu, Lancaster, and Los Angeles. About 70% of the top ten L.A. County neighborhoods at greatest risk are majority-minority areas.
In addition, the company's report provides a more complete and precise picture of community-level risk in the county as public health officials work to target resources to the most vulnerable amid the latest rise in COVID-19 cases.
By combining anonymized health records from California health insurers with publicly available data about vaccination rates, the company was able to identify the communities that have a combination of lagging COVId-19 vaccination rates and large high-risk populations.
This risk analysis can help city officials determine where exactly they should focus their vaccination efforts in the coming weeks as well as help Los Angeles County officials target vaccine outreach resources to the most vulnerable, concluded the company.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine